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Objective: To assess whether tumor necrosis factor (TNF) antagonism can attenuate
eosinophilic airway inflammation in patients with mild-to-moderate allergic asthma.
Design: Randomized, double-blind, placebo-controlled trial.
Setting: National Institutes of Health (NIH) Clinical Center.
Patients: Twenty-six patients with mild-to-moderate allergic asthma, receiving only
inhaled b-2-agonists, who demonstrated both an early and late phase response to
inhalational allergen challenge.
Intervention: Injection of a soluble TNF receptor (TNFR:Fc, etanercept, Enbrel) or
placebo, 25mg subcutaneously, twice weekly for 2 weeks, followed by a
bronchoscopic segmental allergen challenge.
Measurements: The primary outcome measure was whether TNFR:Fc can access the
lung and inhibit TNF bioactivity. Secondary outcome measures included pulmonary
eosinophilia, Th2-type cytokines, and airway hyperresponsiveness.
Results: Anti-TNF therapy was associated with transient hemiplegia in one patient,
which resulted in suspension of the study. Data from the 21 participants who
completed the study were analyzed. Following treatment, patients receiving anti-
TNF therapy had significantly increased TNFR2 levels in epithelial lining fluid (ELF)
(Po0:001), consistent with delivery of TNFR:Fc to the lung. TNF antagonism did not
attenuate pulmonary eosinophilia and was associated with an increase in ELF IL-4ed by Elsevier Ltd.
lavage; BALF, bronchoalveolar lavage fluid; ELF, epithelial lining fluid; FEV1, forced expiratory
inducing a 20% decrease in FEV1; TNF, tumor necrosis factor; TNFR2, 75-kDa, type II tumor
anercept, Enbrel
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F.N. Rouhani et al.1176levels (P ¼ 0:033) at 24 h following segmental allergen challenge. TNF antagonism
was not associated with a change in airway hyperresponsiveness to methacholine.
Conclusions: TNF antagonism may not be effective for preventing allergen-
mediated eosinophilic airway inflammation in mild-to-moderate asthmatics.
Transient hemiplegia, which may mimic an evolving stroke, may be a potential
toxicity of anti-TNF therapy.
Published by Elsevier Ltd.Introduction
Tumor necrosis factor (TNF), a pro-inflammatory
cytokine, plays a key role in disease pathogenesis.1
Further, anti-TNF therapies are effective treat-
ments for rheumatoid arthritis and inflammatory
bowel disease.2,3 Multiple lines of evidence also
support a role for TNF in the pathogenesis of
asthmatic airway inflammation. For example, ele-
vated TNF levels have been found in bronchoalveo-
lar lavage fluid (BALF) from asthmatic patients and
up-regulated TNF expression has been detected in
alveolar macrophages, mast cells, and bronchial
epithelial cells.4–9 TNF induces the expression of
multiple airway epithelial cell genes, including
cytokines (IL-5, IL-6, IL-8, G-CSF, GM-CSF), chemo-
kines (eotaxin, MCP-1, RANTES), adhesion mole-
cules (ICAM-1), extracellular matrix glycoproteins
(tenascin), neuropeptides (endothelin-1), mucins
(MUC-1, MUC-2, MUC-5AC), and cytosolic phospho-
lipase A2.
10–21 TNF increases the adhesion of
activated eosinophils to respiratory epithelial cell
cultures and promotes neutrophil chemotaxis,
adherence, and transendothelial and transepithe-
lial migration.22–24 IgE receptor activation induces
TNF release from human lung tissue and up-
regulates eosinophil TNF mRNA levels.25 An asso-
ciation between asthma and polymorphisms in the
TNF locus that correlate with increased TNF
secretion has been proposed.26–28 Further, admin-
istration of aerosolized TNF to human subjects and
animal models induces airway hyperreactivity and
neutrophilia.29–31 Lastly, anti-TNF strategies have
successfully reduced airway inflammation in animal
models of allergic asthma.32–36
Since clinical and experimental evidence support
a role for TNF in asthma pathogenesis, we reasoned
that anti-TNF therapy might attenuate airway
inflammation in allergic asthmatics. To test this
hypothesis, we administered a dimeric fusion
protein comprising the extracellular ligand-binding
domain of the human 75-kDa, type II TNF receptor
(TNFR2), linked to the Fc portion of human IgG1
(TNFR:Fc, etanercept, Enbrel), to mild-to-moder-
ate allergic asthmatics who demonstrated both
early and late phase responses to inhalational
allergen challenge and assessed its effect on airwayinflammation following a bronchoscopic segmental
allergen challenge.Methods
Study design
This randomized, double-blind, placebo-controlled
study was approved by the National Heart, Lung,
and Blood Institute Institutional Review Board and
conducted between August 1999 and February 2002
at the National Institutes of Health (NIH) Clinical
Center. All study participants provided informed
consent. This trial was designed prospectively to
enroll participants until both the TNFR:Fc and
placebo groups had 13 completers. Allergy was
defined by skin test reactivity to cat dander,
Dermatophagoides farinae, short ragweed, or
Timothy grass using a Multi-Test IIs applicator
(generously provided by Lincoln Diagnostics, Dec-
atur, Illinois). Allergic asthma was established by
reversible airflow obstruction, forced expiratory
volume in 1 s (FEV1)X70% of predicted, medica-
tions limited to inhaled beta-agonists, and both
early and late phase responses to inhalational
allergen challenge. Patients had mild intermittent
or mild/moderate persistent asthma.37 The early
phase response to inhalational allergen challenge
was defined by a 20% decrease in the FEV1 and was
utilized to calculate the antigen PD20. The late
phase response was defined by a 20% decrease in
FEV1 from the baseline established following the
early phase response.
One month following the inhalation allergen
challenge, a baseline bronchoalveolar lavage
(BAL) was performed. Participants were then
randomized in a double-blind fashion to receive
four doses of either TNFR:Fc or placebo (generously
provided by Immunex Corporation, Seattle, Wa-
shington), 25mg subcutaneously, twice per week
for 2 weeks.
Pulmonary function and methacholine challenge
testing were performed following the fourth dose.
A post-drug BAL was performed 24 h after the final
dose, followed by a segmental allergen challenge in
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PD20, and a control saline challenge in the right
upper lobe.38–40 This technique produces a physio-
logically relevant and comparable allergic response
in each participant, as measured by the change in
FEV1 after allergen challenge.
39 BAL was performed
after 5min, to assess the early phase response, and
after 24 h, to assess the late phase response.Bronchoalveolar lavage fluid (BALF) analysis
BALF cell differentials were performed on Diff-
Quik-stained cytospin slides. BALF cytokine mea-
surements were performed by ELISA (R&D Systems,
Minneapolis, MN). All BALF volumes were normal-
ized to epithelial lining fluid (ELF) volume.41Outcome measures
The primary outcome was whether TNFR:Fc could
access the lung and inhibit TNF bioactivity. The
secondary outcomes were pulmonary eosinophilia,
Th2-type cytokines, and airway hyperresponsive-
ness to methacholine.Statistical analysis
We estimated a sample size of 13 in each group to
have an 85% power to detect a difference between
BALF TNF protein levels of 300 pg/ml with an a
error of 0.05.38 The baseline characteristics were
compared utilizing the Wilcoxon–Mann–Whitney
rank-sum test for continuous variables and the
Fisher’s exact test for binary variables. Compar-
isons between the TNFR:Fc and placebo groups
were made at three time points; (i) post-treat-
ment, (ii) early phase response (e.g., 5min follow-
ing segmental allergen challenge), and (iii) late
phase response (e.g., 24 h following segmental
allergen challenge). The differences between the
TNFR:Fc and placebo groups were calculated after
adjusting for the baseline measurement in (i) (e.g.,
post-treatment minus baseline) and after adjusting
for the saline challenge in (ii) and (iii) to control for
the non-specific effects of the bronchoscopy (e.g.,
allergen challenge minus saline challenge) utilizing
the Wilcoxon–Mann–Whitney exact test. Two-sided
P values and 95% confidence intervals are reported.
It was prospectively determined that a P value of
o0.05 would be significant for ELF eosinophils,
Th2-type cytokines, and the methacholine PD20,
while a P value of o0.01 was utilized for all other
analyses.Results
Patient characteristics
There were no statistically significant differences in
baseline characteristics between the TNFR:Fc and
placebo groups (Table 1). Three participants devel-
oped serious adverse events, one of which resulted
in the suspension of the study. This serious adverse
event was a transient left-sided hemiplegia of 36-h
duration, which developed following the third dose
of TNFR:Fc in a patient with no prior history of
neurologic disease. No causal pathology was iden-
tified by CT and MRI imaging. A mild transient
neutropenia was also noted. Two other participants
experienced palpitations and transient neutropenia
while receiving placebo. All serious adverse events
resolved completely without intervention. Eighteen
of the 21 participants returned 1-month following
the completion of the study and reported no
interval change in asthma symptoms. The data
from the 21 participants who completed the study
were analyzed.Pulmonary delivery of TNFR:Fc
After the treatment phase, there was a significant
increase in ELF TNFR2 in the TNFR:Fc group
(Po0:001; 95% confidence interval 9, 33 ng/ml),
consistent with pulmonary delivery of TNFR:Fc (Fig.
1A). There was also a trend toward increased ELF
TNF in the TNFR:Fc group after the treatment
phase (P ¼ 0:06; 95% confidence interval 0.0,
20.2 pg/ml), consistent with TNF binding to TNFR2
(Fig. 1B). BALF TNF bioactivity assays did not yield
reproducible results, therefore, an analysis of TNF
bioactivity could not be performed.Effect of segmental allergen challenge on
ELF cell counts
There were significantly more ELF eosinophils in the
allergen-challenged segment, than in the saline-
challenged segment, at the 24-h time point in both
the TNFR:Fc (Po0:001; 95% confidence interval
8.0 107, 48.2 107 cells) and placebo groups
(P ¼ 0:016; 95% confidence interval 1.3 107,
39.4 107 cells), consistent with the successful
induction of a late phase allergic airway inflamma-
tory response by segmental allergen challenge
(Fig. 2A). There was no difference between ELF
neutrophils (Fig. 2B) in the allergen-challenged
segment and the saline-challenged segment at 24 h
in either the TNFR:Fc or placebo groups.
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Table 1 Characteristics of patients who com-
pleted the study.
Placebo
(N ¼ 9)
TNFR:Fc
(N ¼ 12)
Baseline characteristics
Age (years)
Median 23 27
Range 21–40 20–54
Male 2 8
Female 7 4
FEV1 (l)
Median 3.06 3.29
Range 2.13–4.17 2.67–4.71
FEV1 (% of
predicted)
Median 96 92
Range 79–116 70–114
Methacholine PD20
(mg)
Median 0.06 0.07
Range 0.001–0.49 0.006–0.31
Blood eosinophils
(k/ml)
Median 0.19 0.25
Range 0.05–1.07 0.04–0.54
ELF eosinophils
( 107 cells)
Median 1.34 0.50
Range 0–4.94 0–8.19
Allergen
Cat dander 2 2
D. farinae 4 7
Short ragweed 2 1
Timothy grass 1 2
Adverse events
Bronchospasm 3 1
Dermatitis 1 0
Headache 1 2
Hemiplegia
(transient)
0 1
Injection site
reaction
4 3
Nausea 0 1
Neutropenia 1 1
Palpitations 1 0
Throat dryness 0 1
Viral upper
respiratory tract
Infection
2 0
Denotes serious adverse event.
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There was no significant difference in ELF eosino-
phils, neutrophils, lymphocytes, or macrophages
(Fig. 2) between the TNFR:Fc and placebo groups
following the completion of therapy, or during the
early and late phase responses.
Effect of TNF antagonism on ELF Th2-type
cytokine levels
The TNFR:Fc group had significantly greater ELF
interleukin-4, measured in pg/ml, during the late
phase response to segmental allergen challenge
(P ¼ 0:033; 95% confidence interval 1.2, 9.8 pg/ml)
than did the placebo group (Fig. 3A). ELF IL-5 was
only detected in the allergen-challenged segment
at 24 h and there was no significant difference
between the placebo and TNFR:Fc groups
(P ¼ 0:111; 95% confidence interval 96, 1180 pg/
ml) (Fig. 3B).
Effect of TNF antagonism on airway
hyperresponsiveness and airflow obstruction
There was no difference in airflow obstruction
(Fig. 4A), as determined by the FEV1 in liters
(P ¼ 0:9; 95% confidence interval 0.23, 0.25 L), or
airway hyperresponsiveness (Fig. 4B), as measured
by the methacholine PD20 in milligrams (P ¼ 0:4;
95% confidence interval 0.202, 0.053mg), be-
tween the TNFR:Fc and placebo groups following
TNFR:Fc administration.Discussion
Administration of a recombinant soluble human
TNF receptor for 2 weeks to subjects with mild-to-
moderate allergic asthma did not prevent pulmon-
ary eosinophilia during the late phase response to
bronchoscopic segmental allergen challenge. Since
eosinophils are key effector inflammatory cells in
allergic asthma, our results suggest that TNF
antagonism may not ameliorate allergen-mediated
airway inflammation in mild-to-moderate asth-
matics. Further, TNF antagonism increased pulmon-
ary IL-4 levels, which suggests that TNF signaling
pathways may play a counter-regulatory role by
down-regulating the function of Th2-type T cells.
The ability of TNF to attenuate allergen-
mediated airway inflammation may occur at two
levels. First, chronic TNF stimulation has been
reported to suppress T cell receptor signaling,
proliferative responses, and cytokine production,
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Figure 1 The effect of TNF antagonism on sTNFR2 and TNF in epithelial lining fluid. Data are presented as medians,
with 25th and 75th percentiles (boxes) and 10th and 90th percentiles (I bars). ELF levels of the soluble type II, 75-kDa
tumor necrosis factor receptor (sTNFR2) are presented in panel A and levels of ELF TNF are presented in panel B. The
asterisk in panel A indicates that after the treatment phase, there was a significant increase in ELF TNFR2 levels,
measured in ng/ml, in the TNFR:Fc group (Po0:001; 95% confidence interval 9, 33 ng/ml), consistent with pulmonary
delivery of TNFR:Fc.
Figure 2 The effect of TNF antagonism on cell counts in epithelial lining fluid (ELF). Data are presented as medians,
with 25th and 75th percentiles (boxes) and 10th and 90th percentiles (I bars). ELF cell counts are presented for
eosinophils (panel A), neutrophils (panel B), macrophages (panel C), and lymphocytes (panel D). There was no
significant difference in ELF eosinophil, neutrophil, lymphocyte, or macrophage cell counts between the TNFR:Fc and
placebo groups following the completion of therapy, or during the early and late phase responses.
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Figure 3 The effect of TNF antagonism on IL-4 and IL-5 levels in epithelial lining fluid (ELF). Data are presented as
medians, with 25th and 75th percentiles (boxes) and 10th and 90th percentiles (I bars). ELF fluid levels of interleukin-4
(IL-4) are presented in Panel A and ELF IL-5 levels are presented in panel B. The asterisk in panel A indicates that TNF
antagonism resulted in significantly greater ELF IL-4 levels, measured in pg/ml, in the TNFR:Fc group during the late
phase response to the bronchoscopic segmental allergen challenge (P ¼ 0:033; 95% confidence interval 1.2, 9.8 pg/ml).
Figure 4 The effect of TNF antagonism on airflow obstruction and hyperresponsiveness. Data are presented as medians,
with 25th and 75th percentiles (boxes) and 10th and 90th percentiles (I bars). TNF antagonism had no effect on either
airflow obstruction (Panel A), as measured by the FEV1 in liters (P ¼ 0:9; 95% confidence interval 0.23, 0.25 L), or
airway hyperresponsiveness (panel B), as measured by the methacholine PD20 in milligrams (P ¼ 0:4; 95% confidence
interval 0.202, 0.053mg).
F.N. Rouhani et al.1180thereby negatively regulating the function of both
Th1- and Th2-type T cells.42,43 Conversely, TNF
inhibition enhances T cell proliferation and cyto-
kine production. Second, TNF signaling has been
proposed to repress IL-4 gene expression in Th2-
type T cells via binding of the receptor-associated
factor (TRAF2) to the nuclear factor of activated T
cells (NFAT)-interacting protein (NIP45).44 The
TRAF2-NIP45 interaction suppresses IL-4 production
by inhibiting NIP45/NFATc2/c-maf transactivation
of the IL-4 promoter.44 Therefore, our finding that
anti-TNF therapy amplifies allergen-mediated pul-
monary IL-4 levels is consistent with a potentialcounter-regulatory role for TNF in modulating the
function of Th2-type T cells in allergic asthma.
TNF antagonism may be associated with signifi-
cant neurological effects in a subset of patients,
including case reports of new-onset central nervous
system demyelinating lesions in patients with
inflammatory arthritides and increased disease
activity in multiple sclerosis.45–48 This information
was included in the informed consent document for
our trial, which was suspended following a serious
adverse event of transient hemiplegia. The hemi-
plegia resolved completely following discontinua-
tion of TNFR:Fc and no radiographic or laboratory
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episode. The patient was not re-challenged with
TNFR:Fc. No evidence of central nervous system
demyelination was detected. Although it is not
possible to determine definitively whether this severe
neurologic dysfunction was related to TNFR:Fc, it
raises the concern that transient hemiplegia, which
may closely mimic an evolving stroke, may be a
toxicity related to anti-TNF therapy.
We conclude that TNF antagonism did not prevent
the development of pulmonary eosinophilia in a
segmental allergen challenge model of mild-to-
moderate allergic asthma. Our results also suggest
that TNF may play an important counter-regulatory
role in allergen-mediated airway inflammation.
Further, the possible association between TNF antag-
onism and transient hemiplegia should be considered
in patients who develop new-onset muscular weak-
ness while receiving anti-TNF therapy.Acknowledgements
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